These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12894380)

  • 1. Future immunotherapies in multiple sclerosis.
    Blevins G; Martin R
    Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of multiple sclerosis--current practice and future directions.
    Tullman MJ; Lublin FD; Miller AE
    J Rehabil Res Dev; 2002; 39(2):273-85. PubMed ID: 12051470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific therapies in multiple sclerosis.
    Sospedra M; Martin R
    Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future research directions in multiple sclerosis therapies.
    Greenberg BM; Calabresi PA
    Semin Neurol; 2008 Feb; 28(1):121-7. PubMed ID: 18256992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy.
    Kieseier BC; Archelos JJ; Storch M; Gold R; Hartung HP
    Wien Klin Wochenschr; 1999 Sep; 111(17):728-37. PubMed ID: 10526397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: MHC associations and therapeutic implications.
    Holmes S; Friese MA; Siebold C; Jones EY; Bell J; Fugger L
    Expert Rev Mol Med; 2005 Feb; 7(3):1-17. PubMed ID: 15710050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunological basis for treatment of multiple sclerosis.
    Holmøy T; Vartdal F
    Scand J Immunol; 2007 Oct; 66(4):374-82. PubMed ID: 17850581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic approaches in multiple sclerosis.
    Adorini L
    J Neurol Sci; 2004 Aug; 223(1):13-24. PubMed ID: 15261555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O; Stüve O; Archelos JJ; Hartung HP
    J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
    Fontoura P; Garren H; Steinman L
    Int Rev Immunol; 2005; 24(5-6):415-46. PubMed ID: 16318989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Other immunomodulatory therapies in multiple sclerosis.
    Polman CH
    Baillieres Clin Neurol; 1997 Oct; 6(3):511-24. PubMed ID: 10101587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of multiple sclerosis--2. Application of a new immunological basic research is close].
    Svenningsson A; Andersson M; Olsson T
    Lakartidningen; 1998 Dec; 95(49):5631-5. PubMed ID: 9863301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.